Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

Mise à jour : Il y a 4 ans
Référence : NCT00808223

Femme et Homme

Extrait

To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.


Critère d'inclusion

  • Psoriasis

Liens